Strike Pharma
Strike Pharma is a Swedish biotech company developing in vivo CAR-T therapies for autoimmune disease and cancer based on a proprietary technology for targeted LNP delivery. Founded in 2020, it leverages scientific discoveries from Uppsala University and SciLifeLab, with main investors including Eir Ventures, Flerie Invest, Almi Invest, AB Ility, and Monesi Förvaltnings AB. The company's mission is to enable targeted nanoparticle delivery for innovative immunotherapies, aiming to improve treatment options for autoimmune diseases and cancers.
Industries
Nr. of Employees
small (1-50)
Products
Affinity-based targeted delivery platform for nanoparticles
A platform combining a short peptide tag attached to payloads (including LNPs) and scFv-linked targeting units to enable modular, high-affinity, cell-specific delivery of diverse payloads (peptides, RNA, oligonucleotides).
Lead preclinical in vivo CAR-T candidate targeting B cells
A preclinical candidate consisting of T-cell-directed LNPs carrying CAR-encoding mRNA, combined with a bispecific targeting antibody that delivers the LNP to T cells to generate B-cell-targeting CAR-Ts in vivo; intended for B-cell-dependent autoimmune disease and oncology indications.
Affinity-based targeted delivery platform for nanoparticles
A platform combining a short peptide tag attached to payloads (including LNPs) and scFv-linked targeting units to enable modular, high-affinity, cell-specific delivery of diverse payloads (peptides, RNA, oligonucleotides).
Lead preclinical in vivo CAR-T candidate targeting B cells
A preclinical candidate consisting of T-cell-directed LNPs carrying CAR-encoding mRNA, combined with a bispecific targeting antibody that delivers the LNP to T cells to generate B-cell-targeting CAR-Ts in vivo; intended for B-cell-dependent autoimmune disease and oncology indications.
Services
Collaborative research and development partnerships
Joint projects and agreements with academic and industry partners for platform validation, cell line development, and candidate advancement.
Collaborative research and development partnerships
Joint projects and agreements with academic and industry partners for platform validation, cell line development, and candidate advancement.
Expertise Areas
- In vivo CAR-T development
- Targeted nanoparticle delivery
- Bispecific antibody engineering
- Peptide cargo delivery and vaccine-style antigen presentation
Key Technologies
- Lipid nanoparticle (LNP) delivery
- mRNA therapeutics (non-viral delivery)
- Affinity tag–scFv conjugation platform
- Bispecific antibody formats